Find Clinical Trial

Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

Active substance/
Medical device

S020098, AGOMELATINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS020098
Protocol CodeCL3-20098-073
EudraCT Code2010-019556-44
ISRCTN CodeISRCTN97599615


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility